Papillary renal cell carcinoma and clear cell renal cell carcinoma: Differentiation of distinct histological types with contrast – enhanced ultrasonography

Xue, Li-yun; Lü, Qing; Huang, Beijian; Li, Zheng; Li, Cui-Xian; Wen, Jian; Wang, Wenping

doi:10.1016/j.ejrad.2015.06.017

Cited by 28 publications

(24 citation statements)

References 26 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The wash-in pattern was classified into slow-in and simultaneous-in, and the wash-out pattern was classified into fast- or simultaneous-out and slow-out. The degree of tumour at peak enhancement was divided into hypo-, iso-, and hyperenhancement compared with the adjacent renal cortex [12]. The homogeneity of enhancement was classified into homogeneous and heterogeneous [13].…”

Section: Methodsmentioning

confidence: 99%

Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma

et al. 2019

View full text Add to dashboard Cite

BackgroundTo investigate the contrast-enhanced ultrasound (CEUS) findings of renal cell carcinoma (RCC) associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2/TFE3) in adult patients by comparison with those of clear cell RCC (ccRCC) and papillary RCC (pRCC).MethodsIn total, 110 patients (110 renal masses) who underwent CEUS examinations were enrolled in this study. The cases included 18 Xp11.2/TFE3 RCCs, 60 ccRCCs and 32 pRCCs. All masses were confirmed by operative pathology. The CEUS imaging data of these patients were retrospectively analysed by two readers. The conventional US and CEUS features of Xp11.2/TFE3 RCC were compared with those of ccRCC and pRCC.ResultsThe age of the patients with Xp11.2/TFE3 RCC ranged from 20 to 68 years, with a mean age of 38.3 ± 16.3 years and a slight female predominance. The weighted kappa value that interprets the concordance between the interobserver agreement of the US and CEUS features ranged from 0.61 to 0.89. On conventional US and CEUS imaging of Xp11.2/TFE3 RCCs, the tumours were hypoechoic (6/18, 33.3%), isoechoic (8/18, 44.4%), and hyperechoic (4/18, 22.2%). The cystic component was present in 5 cases (27.8%), calcification was present in 9 cases (50.0%), and colour flow signal was present in 7 cases (38.9%). Most cases showed simultaneous wash-in (11/18, 61.1%); the peak enhancement showed hypoenhancement (6/18, 33.3%), isoenhancement (10/18, 55.6%), and hyperenhancement (2/18, 11.1%); most cases exhibited heterogeneous enhancement (12/18, 66.7%) and fast- or simultaneous-out (16/18, 88.9%); and a pseudocapsule was present in 6 cases (33.3%). In the multivariate logistic regression analysis, calcification and lower peak enhancement were more likely to be present in Xp11.2/TFE3 RCC than in ccRCC (P < 0.05), and younger age and relatively high peak enhancement were more likely to be present in Xp11.2/TFE3 RCC than in pRCC (P < 0.05). The calcification combined peak enhancement model differentiated Xp11.2/TFE3 RCC from ccRCC, and the age combined peak enhancement model differentiated Xp11.2/TFE3 RCC from pRCC with an AUC, a sensitivity and a specificity of 0.896, 94.4% and 73.3% and 0.786, 50.0% and 100.0%, respectively.ConclusionsThe specific CEUS features combined with demographic information and clinical symptoms may be helpful for differentiating Xp11.2/TFE3 RCC from ccRCC and pRCC.

show abstract

Section: Methodsmentioning

confidence: 99%

Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Compared with contrast agents used in CT, US contrast agents are free of ionizing radiation and can be used in patients with renal dysfunction or iodine allergies, for whom enhanced CT and MRI may be contraindicative. Currently, an increasing number of studies use CEUS to investigate tumor angiogenesis, which has been validated in differentiating malignant masses from benign ones in the liver, kidney, breast, and thyroid . Recently, Tang et al concluded that cardiac thrombi and benign and malignant tumors had different degrees of enhancement on CEUS, and assessment of the degree of enhancement of cardiac masses had high diagnostic accuracy in the differentiation of a thrombus from a tumor or a benign tumor from a malignant tumor.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Value of Transthoracic Echocardiography Combined With Contrast‐Enhanced Ultrasonography in Mediastinal Masses

Wang

Zhang

Liu

et al. 2018

J of Ultrasound Medicine

View full text Add to dashboard Cite

show abstract

“…Renal cell carcinoma (RCC) demonstrates rapid enhancement and wash‐out on delayed images. There are some reports suggesting that the enhancement pattern may classify the type of RCC . Often, a Hampton hump is identified on unenhanced ultrasound with the concern of a solid renal mass.…”

Section: Discussionmentioning

confidence: 99%

How to Develop a Contrast-Enhanced Ultrasound Program

Barr

2017

J Ultrasound Med

View full text Add to dashboard Cite

With the recent Food and Drug Administration approval of Lumason (sulfur hexafluoride lipid-type A microsphere, Bracco Diagnostics Inc, Monroe Township, NJ) for contrast-enhanced ultrasound (CEUS) to characterize focal liver lesions in both adult and pediatric patients, widespread use of CEUS is expected in the United States. This paper provides guidance in setting up a CEUS program, and reviews the practical details that will need to be instituted in a standard ultrasound department to provide both safe and efficient use of CEUS. A review of the indications, contraindications, adverse events, instructions for performing the exam, and image interpretation are discussed.

show abstract

Papillary renal cell carcinoma and clear cell renal cell carcinoma: Differentiation of distinct histological types with contrast – enhanced ultrasonography

Cited by 28 publications

References 26 publications

Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma

Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma

Diagnostic Value of Transthoracic Echocardiography Combined With Contrast‐Enhanced Ultrasonography in Mediastinal Masses

How to Develop a Contrast-Enhanced Ultrasound Program

Contact Info

Product

Resources

About